Open AccessComplete Response With Immunotherapy: A Case of Metastatic Bladder Cancer
Author(s) -
Balraj Singh,
Parminder Kaur,
Sachin Gupta,
Nirmal Guragai,
Michael Maroules
Publication year - 2021
Publication title -
journal of investigative medicine high impact case reports
Language(s) - English
Resource type - Journals
ISSN - 2324-7096
DOI - 10.1177/23247096211035603
Subject(s) - medicine , pembrolizumab , immunotherapy , malignancy , bladder cancer , chemotherapy , oncology , cancer , metastatic urothelial carcinoma , urothelial carcinoma
Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.